Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)

USD 56.04

(14.37%)

Net Income Summary of Recordati Industria Chimica e Farmaceutica S.p.A.

  • Recordati Industria Chimica e Farmaceutica S.p.A.'s latest annual net income in 2023 was 389.21 Million EUR , up 24.61% from previous year.
  • Recordati Industria Chimica e Farmaceutica S.p.A.'s latest quarterly net income in 2024 Q1 was 123.59 Million EUR , up 45.88% from previous quarter.
  • Recordati Industria Chimica e Farmaceutica S.p.A. reported an annual net income of 312.33 Million EUR in 2022, down -19.08% from previous year.
  • Recordati Industria Chimica e Farmaceutica S.p.A. reported an annual net income of 385.96 Million EUR in 2021, up 8.73% from previous year.
  • Recordati Industria Chimica e Farmaceutica S.p.A. reported a quarterly net income of 101.77 Million EUR for 2024 Q2, down -17.65% from previous quarter.
  • Recordati Industria Chimica e Farmaceutica S.p.A. reported a quarterly net income of 84.72 Million EUR for 2023 Q4, up 10.14% from previous quarter.

Annual Net Income Chart of Recordati Industria Chimica e Farmaceutica S.p.A. (2023 - 2003)

Historical Annual Net Income of Recordati Industria Chimica e Farmaceutica S.p.A. (2023 - 2003)

Year Net Income Net Income Growth
2023 389.21 Million EUR 24.61%
2022 312.33 Million EUR -19.08%
2021 385.96 Million EUR 8.73%
2020 354.98 Million EUR -3.75%
2019 368.82 Million EUR 18.07%
2018 312.37 Million EUR 8.18%
2017 288.76 Million EUR 21.63%
2016 237.4 Million EUR 19.42%
2015 198.79 Million EUR 23.33%
2014 161.18 Million EUR 20.58%
2013 133.67 Million EUR 12.82%
2012 118.48 Million EUR 1.76%
2011 116.43 Million EUR 7.24%
2010 108.57 Million EUR -1.8%
2009 110.56 Million EUR 10.09%
2008 100.42 Million EUR 18.33%
2007 84.86 Million EUR 14.63%
2006 74.03 Million EUR 14.7%
2005 64.54 Million EUR 21.48%
2004 53.13 Million EUR 123.73%
2003 23.74 Million EUR 0.0%

Peer Net Income Comparison of Recordati Industria Chimica e Farmaceutica S.p.A.

Name Net Income Net Income Difference
AstraZeneca PLC 5.95 Billion USD 93.464%
Bristol-Myers Squibb Company PFD CONV 2 8.02 Billion USD 95.15%
CSPC Pharmaceutical Group Limited 830.91 Million USD 53.158%
Clarus Therapeutics Holdings, Inc. -56.51 Million USD 788.728%
Novartis AG 14.85 Billion USD 97.379%
PT Kalbe Farma Tbk. 179.7 Million USD -116.584%